J Rheum Dis 2020; 27(3): 168-173  
Analysis of Asian Mitochondrial DNA Haplogroups Associated With the Progression of Knee Osteoarthritis in Koreans
Bon San Koo, M.D.1, Yoonah Song, M.D.2, Seunghun Lee, M.D., Ph.D.2, Yoon-Kyoung Sung, M.D., Ph.D.3, Kyoung-Jin Shin, M.D., Ph.D.4, Nam H. Cho, M.D., Ph.D.5, Jae-Bum Jun, M.D., Ph.D.3
1Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Departments of 2Radiology and 3Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 4Department of Forensic Medicine, Yonsei University College of Medicine, Seoul, 5Department of Preventive Medicine, Ajou University School of Medicine, Suwon, Korea
Correspondence to: Jae-Bum Jun http://orcid.org/0000-0002-0208-0505
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. E-mail:junjb@hanyang.ac.kr
Received: December 5, 2019; Revised: April 22, 2020; Accepted: May 7, 2020; Published online: July 1, 2020.
© Korean College of Rheumatology.

This is a open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. We investigated Asian mitochondrial DNA (mtDNA) haplogroups associated with knee osteoarthritis (OA) progression in a prospective community-based cohort comprised of Koreans. Methods. Epidemiologic data and Kellgren-Lawrence (K/L) scores of knee radiographs were obtained from the second (2005∼2006) and sixth (2013∼2014) follow-up, and patient DNA was analyzed. The mtDNA haplogroup frequencies (M, G, D, D4, D5, M7, M8, M9, M10, N, A, N9, R, F, and B) were compared between the progression (K/L score change on either knee ≥2 or arthroplasty) and non-progression (K/L score change on both knee ≤1) groups at the sixth follow-up. Multiple logistic regression was performed to determine relative risk (RRs) of mtDNA haplogroups for OA. Results. In total, 1,115 participants were included, 405 of whom had early OA (higher K/L score on both knees of 1 or 2). Among them, 143 and 166 patients were classified in non-progression and progression groups, respectively, at the sixth follow-up. The most frequent haplogroups, B and D4, in Koreans also showed a high frequency in our study. There were no significantly different haplogroups between the non-progression and progression groups. However, the frequency of haplogroup D4 was likely higher in the non-progression group than in the progression group, although not significantly (13.3% vs. 7.2%, RR=0.51, p=0.081 in the unadjusted model and RR=0.56, p=0.149 in the adjusted model). Conclusion. No significant haplogroups are related to OA progression. Large-scaled studies are needed to reveal the association between mtDNA haplogroups and OA.
Keywords: Korea, Mitochondrial DNA, Osteoarthritis of the knee

Osteoarthritis (OA) is the most common degenerative disease related to the degradation of articular cartilage. Many studies have been performed to evaluate the relationship between OA and mitochondrial DNA (mtDNA). Changes in intracellular signals such as in mitochondrial respiratory chain activity in chondrocytes may be associated with degenerative changes in cartilage affected by low-grade chronic inflammation [1].

In a previous study, we examined whether mtDNA haplogroup B contributed to the development of knee OA in Koreans, measured as radiologic changes for approximately 8 years in a large-scale prospective cohort [2]. Identifying the relationship between the haplogroup of mitochondria and development of OA is important for identifying the risk factors of chronic disease [3-8]. However, considering the nature of OAs, which are characterized by very long-term changes, it is also important to identify factors that can predict which patients with OA are experiencing rapid OA progression.

Various cohort studies have reported that specific mtDNA haplogroups are also associated with the radiographic progression of OA [9-11]. They suggested that haplogroups associated with progression differed from the mtDNA haplogroup involved in OA development. Therefore, to determine which mtDNA haplogroups are associated with OA progression in Koreans, we developed a new study design based on a previous study protocol [2].

The aim of this study was to investigate Asian mtDNA haplogroups associated with the progression of knee OA in participants in a prospective ongoing community-based cohort in Korea.


Study design and participants

As described in our previous study [2], we used the Ansung cohort of an ongoing, prospective cohort study that is part of the Korean Genome and Epidemiology Study [12]. In the present study, mtDNA haplogroups related to the progression of OA were examined by modifying the experimental design of the previous study. Briefly, epidemiologic data and Kellgren-Lawrence (K/L) scores of the knee radiographs were obtained from the second follow-up (2005∼2006) and sixth follow-up (2013∼2014) of this cohort. The K/L scores were measured by an orthopedist (KKI) and radiologist (SY) at the second follow-up visit with excellent inter-observer correlation coefficients and by a radiologist (SY) at the sixth follow-up visit with excellent intra-observer correlation coefficients [13]. The institutional review boards of all involved institutions approved this study (approval no. HYUH 2015-12-022).

Overall, there were 5,018 participants, and we obtained DNA samples from 1,115 participants (Figure 1). We defined early OA as a higher K/L score for both knees of 1 or 2 at the second follow-up to identify progression, rather than as a criterion for the development of OA, as in previous studies of the association between mtDNA and OA development [11]. Among the participants, 405 met the definition of early OA at the second follow-up and were divided into two groups: K/L score change ≤1 in both knees (non-progression group, n=143) and K/L score change ≥2 in either knee or arthroplasty (progression group, n=166) at the sixth follow-up. All missing values for the K/L score at the sixth follow-up were excluded (n=96).

Figure 1. Classification according to the Kellgren-Lawrence (K/L) score at each follow-up in the study cohort. The frequencies of mitochondrial DNA haplogroups were analyzed in the non-progression and progression groups (box surrounded by the dotted line).

mtDNA haplogroup genotyping

Blood samples were stored in the Korea Biobank Network, Center for Disease Control at the second follow-up visit (2005∼2006). Asian mtDNA haplogroups (M, G, D, D4, D5, M7, M8, M9, M10, N, A, N9, R, F, and B) were determined by multiplex mutagenetically separated polymerase chain reaction. Single-nucleotide polymorphisms at positions 15043, 4833, 4883, 3010, 1107, 9824, 7196, 4491, 13152, 10873, 8794, 5417, 12705, and 6392 and a 9-base pair deletion at position 8281 to 8289 were selected and analyzed as described by Lee et al. [14].

Statistical analysis

Differences between the non-progression and progression groups at the sixth follow-up were investigated by Student t-test and the Pearson chi-square test. Multiple logistic regression was used to determine the relative risk (RR) of mtDNA haplogroups for OA by adjusting for sex, age, and body mass index (BMI) because the incidence of knee OA is high in women and the elderly and obesity is a risk factor for OA [15]. Smoking and metabolic syndrome were excluded from the adjusted model because these factors are correlated with sex and BMI, respectively. p-values<0.05 indicated statistical significance. All statistical analyses were performed using PASW software version 18.0 (IBM Co., Armonk, NY, USA).


Baseline clinical characteristics

The clinical characteristics of the participants are described in Table 1. There were no significant differences in age between the non-progression and progression groups. The number of females was significantly higher in the progression group than in the non-progression group (88.6% vs. 76.9%, respectively). The rates of smoking, drinking, and diabetes, and hypertension were not significantly different between groups. However, the BMI and rates of metabolic syndrome were significantly higher in the progression group than in the non-progression group (26.74±3.21 vs. 25.33±3.26 and 77.7% vs. 62.0%, respectively).

Table 1 . Clinical characteristics of participants included in the cohort.

VariableNon-progression (n=143)Progression (n=166)p-valuep-value*
Age (yr)62.47±8.2262.88±6.170.624-
Sex, female110 (76.9)147 (88.6)0.0060.007
Body mass index (kg/m2)25.33±3.2626.74±3.21<0.001<0.001
Smoking, ever/current26 (18.2)19 (11.4)0.0940.087
Drinking, ever/current53 (37.1)48 (28.9)0.1280.134
Diabetes34 (24.3)31 (18.9)0.2540.234
Hypertension70 (49.0)95 (57.2)0.1460.162
Metabolic syndrome88 (62.0)129 (77.7)0.0030.003

Values are presented as mean±standard deviation or number (%). *Age-adjusted..

mtDNA haplogroups associated with non-progression and progression of OA

The haplogroup frequencies of the non-progression and progression groups and RRs are shown in Table 2. Among the haplogroups, haplogroups B and D4 showed the highest frequencies (15.9% and 10.0%, respectively). In multiple logistic regression analysis, there was no significant RR for the progression of OA in each haplogroup in the unadjusted model, adjusted model for age, sex, and BMI, and adjusted model for age, sex, BMI, smoking, and metabolic syndrome. Among the haplogroups, the proportion of non-progression patients in haplogroup D4 was likely higher than that in patients showing progression; however, there was also no significant difference between the two groups (13.3% vs. 7.2%, RR=0.51 [0.24∼1.09], p=0.081 in unadjusted model and RR=0.56 [0.25∼1.23], p=0.149 in adjusted model for age, sex, BMI).

Table 2 . Multiple logistic regression analysis of mitochondrial haplogroups associated with osteoarthritis.

HaplogroupNon-progression (n=143)Progression (n=166)UnadjustedAdjusted*

BRR (95% CI)p-valueBRR (95% CI)p-value
A14 (9.8)16 (9.6)−0.0170.98 (0.46∼2.09)0.964−0.1670.85 (0.38∼1.87)0.680
B21 (14.7)28 (16.9)0.1641.18 (0.64∼2.18)0.6010.1851.20 (0.63∼2.28)0.571
D1 (0.7)0 (0.0)−21.359-1.000−20.721-1.000
D419 (13.3)12 (7.2)−0.6760.51 (0.24∼1.09)0.081−0.5860.56 (0.25∼1.23)0.149
D4a9 (6.3)9 (5.4)−0.1580.85 (0.33∼2.21)0.744−0.2320.79 (0.30∼2.12)0.644
D4b2 (1.4)1 (0.6)−0.8500.43 (0.04∼4.76)0.489−0.6370.53 (0.05∼6.06)0.608
D4b29 (6.3)11 (6.6)0.0551.06 (0.42∼2.63)0.9060.1121.12 (0.44∼2.87)0.816
D4j3 (2.1)2 (1.2)−0.5640.57 (0.09∼3.45)0.5400.0171.02 (0.15∼6.77)0.986
D4e4 (2.8)7 (4.2)0.4251.53 (0.44∼5.34)0.5050.4011.49 (0.41∼5.39)0.540
D4a/D4b0 (0.0)1 (0.6)21.060-1.00020.804-1.000
D512 (8.4)13 (7.8)−0.0750.93 (0.41∼2.10)0.8570.0031.00 (0.43∼2.34)0.994
F11 (7.7)17 (10.2)0.3141.37 (0.62∼3.03)0.4380.2771.32 (0.58∼2.99)0.508
G8 (5.6)11 (6.6)0.1801.20 (0.47∼3.06)0.7070.1841.20 (0.46∼3.16)0.709
M1 (0.7)2 (1.2)0.5491.73 (0.16∼19.30)0.6550.4881.63 (0.14∼18.47)0.694
M79 (6.3)12 (7.2)0.1491.16 (0.47∼2.84)0.7450.0491.05 (0.42∼2.62)0.916
M88 (5.6)11 (6.6)0.1801.20 (0.47∼3.06)0.707−0.0100.99 (0.37∼2.63)0.984
M93 (2.1)2 (1.2)−0.5640.57 (0.09∼3.45)0.540−0.3840.68 (0.11∼4.26)0.681
M102 (1.4)0 (0.0)−21.366-0.999−22.129-0.999
N97 (4.9)11 (6.6)0.3211.38 (0.52∼3.66)0.5190.3981.49 (0.54∼4.10)0.440
R0 (0.0)0 (0.0)------
Macro-haplogroup M90 (62.9)94 (56.6)−0.2630.77 (0.49∼1.21)0.260−0.2270.80 (0.50∼1.28)0.348
Macro-haplogroup N53 (37.1)72 (43.4)0.2631.30 (0.82∼2.06)0.2600.2271.26 (0.78∼2.02)0.348
Macro-haplogroup D§59 (41.3)56 (33.7)−0.3220.72 (0.46∼1.15)0.173−0.2090.81 (0.50∼1.31)0.394
Macro-haplogroup R32 (22.4)45 (27.1)0.2551.29 (0.77∼2.17)0.3380.2551.29 (0.75∼2.22)0.357

Values are presented as number (%). RR: relative risk, CI: confidence interval. *Adjusted for age, sex, body mass index. Macro-haplogroupM: D, D4, D4a, D4b, D4b2, D4j, D4e, D4a/D4b, D5, G, M, M7, M8, M9, and M10. Macro-haplogroup N: A, B, F, N9, and R. §Macro-haplogroup D: D, D4, D4a, D4b, D4b2, D4j, D4e, D4a/D4b, and D5. Macro-haplogroup R: B, F, and R..


Our previous study suggested that participants with haplogroup B had a higher risk of OA development [2]. In the present study, we observed no significant relationship between the haplogroups and OA progression. Haplogroup B, which was associated with the development of OA in our previous study [2], appeared to be related to OA progression but did not show a significant difference in the present study. Haplogroup D4 showed a low frequency in the progression group but the value was not significant.

Several studies in western countries have described the relationship between OA progression and mtDNA haplogroups. Soto-Hermida et al. [10] found that patients with haplogroup T had the lowest increase in K/L score (hazard ratio=0.499; 95% confidence interval [95% CI]: 0.261∼0.815) and in other radiographic indicators for progression such as joint space narrowing, osteophytes, and subchondral sclerosis. They also studied OA progression and mtDNA haplogroups in a Spanish cohort [11]. Patients in cluster TJ showed slower radiographic OA progression than patients in cluster KU (hazard ratio=1.711; 95% CI: 1.037∼2.823).

In a case-control study of Asians, Fang et al. [16] reported that haplogroup G increased the risk of OA occurrence (OA group 4.3% vs. control 1.4%, odds ratio [OR]=3.834; p=0.03) and patients with haplogroup G showed a higher severity of progression (K/L score 4) of knee OA (OR=10.870, p=0.007). Additionally, they showed that haplogroup D4/D4a was related to the higher-severity OA. Although the designs of their studies differed from those of our cohort study, the frequency of haplogroup D4 may be lower in the progression group than in the non-progression group. In East Asians, the frequent sequence variations in the Korean population were very similar to those in Japanese and Northern Chinese populations [17]. However, the frequency of the haplogroups related to disease may vary by country.

In the previous study investigating the progression of OA, a K/L score change ≥1 was defined as OA progression [10,11]. However, we defined K/L score change >2 as a progression after approximately 8 years among patients who had a higher K/L score in both knees of 1 or 2 at the second (baseline) follow-up. Even when using this strict definition of OA progression, no meaningful haplogroup was identified. This result is thought to be related to the small number of participants defined as having early OA. However, this is the only study in Korea to evaluate the association between knee OA progression and mtDNA haplogroups. Additional large-scale studies are necessary to identify the mtDNA haplogroup related to OA, which will improve the early diagnosis and prevention in patients at a high risk of OA.

Several studies have suggested that haplogroup D4 is related to type 2 diabetes mellitus (DM). Liou et al. [18] suggested that haplogroup B4 was significantly associated with DM (OR 1.54 [95% CI 1.18∼2.02], p< 0.001), whereas haplogroup D4 showed borderline resistance against type 2 DM (OR 0.68 [95% CI 0.49∼0.94], p=0.02) in a Chinese population in Taiwan [18]. However, Jiang et al. [19] suggested that haplogroup D4 is associated with an increased risk of developing type 2 DM (OR 1.47 [95% CI 1.22∼1.77], p<0.01) in a Uyghur population in China and that the 3010G>A variant is likely involved in the pathogenesis of type 2 DM. Fuku et al. [20] also suggested that haplogroup D4b in Korean men was associated with an increased risk of DM (OR 3.55 [95% CI 1.65∼8.34], p<0.01). Although the relationship between DM and haplogroup D4 shows variable results, considering that DM is associated with OA [21], haplogroup D4 may be associated with OA in Koreans.

Our study had several limitations. First, we investigated the progression of knee OA according to the K/L score change in knee radiographs after approximately 8 years. This follow-up period may not be sufficient to observe the progression of OA on knee radiographs. Long-term research designs using elaborate degenerative change screening methods are required to acquire more participants. Second, knee OA is generally defined as a K/L score of 2 or more; however, in our study, participants with a K/L score ≥1 at baseline were defined as having OA, as described previously [11]. Although the definition we used led to a larger number of participants, the sample size was still too small to obtain meaningful results. Third, although the parameters were adjusted for OA progression, we also need to consider variables related to risk factors for OA, such as anatomic factors, bone density, and physical activity. Fourth, functional scores such as the Western Ontario and McMaster Universities (WOMAC) is important for evaluating dysfunction in patients with OA. However, this information was not available for the Ansung cohort. The WOMAC score can complement the definition of progression by the K/L score.


In conclusion, no mtDNA haplogroup was found to be associated with the progression of OA in Koreans. Although not significant, haplogroup D4 may be associated with slower progression of OA. Large-scale studies are needed to determine the relationship between mtDNA haplogroups and OA.


This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2015R1D1A1A01057559).


No potential conflict of interest relevant to this article was reported.


B.S.K, Y.K.S, and J.B.J. were involved in conception and design, interpretation of data. K.J.S. and N.H.C were involved in acquisition and analysis of data. Y.S., S.L., K.J.S., N.H.C., and J.B.J. were involved in acquisition and interpretation of data. All authors were involved in drafting and revising the manuscript critically for important intellectual content and final approval of the version to be published.

  1. Blanco FJ, Valdes AM, Rego-Pérez I. Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes. Nat Rev Rheumatol 2018;14:327-40.
    Pubmed CrossRef
  2. Koo BS, Song Y, Lee S, Sung YK, Shin KJ, Cho NH, et al. Association of Asian mitochondrial DNA haplogroup B with new development of knee osteoarthritis in Koreans. Int J Rheum Dis 2019;22:411-6.
    Pubmed CrossRef
  3. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat Rev Rheumatol 2011;7:161-9.
    Pubmed CrossRef
  4. Fernández-Moreno M, Soto-Hermida A, Vázquez-Mosquera ME, Cortés-Pereira E, Relaño S, Hermida-Gómez T, et al. Mitochondrial DNA haplogroups influence the risk of incident knee osteoarthritis in OAI and CHECK cohorts. A meta-analysis and functional study. Ann Rheum Dis 2017;76:1114-22.
    Pubmed CrossRef
  5. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyère O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013;72:1756-63.
    Pubmed KoreaMed CrossRef
  6. Minafra L, Bravatà V, Saporito M, Cammarata FP, Forte GI, Caldarella S, et al. Genetic, clinical and radiographic signs in knee osteoarthritis susceptibility. Arthritis Res Ther 2014;16:R91.
    Pubmed KoreaMed CrossRef
  7. Rego I, Fernández-Moreno M, Fernández-López C, Gómez-Reino JJ, González A, Arenas J, et al. Role of European mitochondrial DNA haplogroups in the prevalence of hip osteoarthritis in Galicia, Northern Spain. Ann Rheum Dis 2010;69:210-3.
    Pubmed CrossRef
  8. Rego-Pérez I, Fernández-Moreno M, Fernández-López C, Arenas J, Blanco FJ. Mitochondrial DNA haplogroups: role in the prevalence and severity of knee osteoarthritis. Arthritis Rheum 2008;58:2387-96.
    Pubmed CrossRef
  9. Fernández-Moreno M, Soto-Hermida A, Vázquez-Mosquera ME, Cortés-Pereira E, Pértega S, Relaño S, et al. A replication study and meta-analysis of mitochondrial DNA variants in the radiographic progression of knee osteoarthritis. Rheumatology (Oxford) 2017;56:263-70.
    Pubmed KoreaMed CrossRef
  10. Soto-Hermida A, Fernández-Moreno M, Oreiro N, Fernández-López C, Pértega S, Cortés-Pereira E, et al. Mitochondrial DNA (mtDNA) haplogroups influence the progression of knee osteoarthritis. Data from the Osteoarthritis Initiative (OAI). PLoS One 2014;9:e112735.
    Pubmed KoreaMed CrossRef
  11. Soto-Hermida A, Fernández-Moreno M, Pértega-Díaz S, Oreiro N, Fernández-López C, Blanco FJ, et al. Mitochondrial DNA haplogroups modulate the radiographic progression of Spanish patients with osteoarthritis. Rheumatol Int 2015;35:337-44.
    Pubmed CrossRef
  12. Cho NH, Kim JY, Kim SS, Shin C. The relationship of metabolic syndrome and constitutional medicine for the prediction of cardiovascular disease. Diabetes Metab Syndr 2013;7:226-32.
    Pubmed CrossRef
  13. Cho NH, Song Y, Lee S, Sung YK, Jun JB. Incidence of knee chondrocalcinosis and its risk factors in a community-based cohort. Int J Rheum Dis 2018;21:1391-7.
    Pubmed CrossRef
  14. Lee HY, Yoon JA, Yang WI, Shin KJ. A one step multiplex PCR assay for rapid screening of East Asian mtDNA haplogroups on forensic samples. Leg Med (Tokyo) 2013;15:50-4.
    Pubmed CrossRef
  15. Allen KD, Golightly YM. State of the evidence. Curr Opin Rheumatol 2015;27:276-83.
    Pubmed KoreaMed CrossRef
  16. Fang H, Zhang F, Li F, Shi H, Ma L, Du M, et al. Mitochondrial DNA haplogroups modify the risk of osteoarthritis by altering mitochondrial function and intracellular mitochondrial signals. Biochim Biophys Acta 2016;1862:829-36.
    Pubmed CrossRef
  17. Park S, Cho S, Seo HJ, Lee JH, Kim MY, Lee SD. Entire mitochondrial DNA sequencing on massively parallel sequencing for the Korean population. J Korean Med Sci 2017;32:587-92.
    Pubmed KoreaMed CrossRef
  18. Liou CW, Chen JB, Tiao MM, Weng SW, Huang TL, Chuang JH, et al. Mitochondrial DNA coding and control region variants as genetic risk factors for type 2 diabetes. Diabetes 2012;61:2642-51.
    Pubmed KoreaMed CrossRef
  19. Jiang W, Li R, Zhang Y, Wang P, Wu T, Lin J, et al. Mitochondrial DNA mutations associated with type 2 diabetes mellitus in Chinese uyghur population. Sci Rep 2017;7:16989.
    Pubmed KoreaMed CrossRef
  20. Fuku N, Park KS, Yamada Y, Nishigaki Y, Cho YM, Matsuo H, et al. Mitochondrial haplogroup N9a confers resistance against type 2 diabetes in Asians. Am J Hum Genet 2007;80:407-15.
    Pubmed KoreaMed CrossRef
  21. Williams MF, London DA, Husni EM, Navaneethan S, Kashyap SR. Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis. J Diabetes Complications 2016;30:944-50.
    Pubmed CrossRef

This Article

Author ORCID Information

Funding Information

Social Network Service